An open label phase II trial of rituximab (IDEC-C2B8) in patients with mantle cell lymphoma, lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinaemia and small lymphocytic lymphoma

Trial Profile

An open label phase II trial of rituximab (IDEC-C2B8) in patients with mantle cell lymphoma, lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinaemia and small lymphocytic lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2005

At a glance

  • Drugs Rituximab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 03 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top